IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
Lung
This session provides a comprehensive overview of the complex in vitro models (CIVMs) commonly employed by lung safety teams in the drug development process. Participants will gain a thorough understanding of the functional characterization of these models and how they are rigorously qualified for use through testing with tool compounds known to exhibit lung safety liabilities.
Through real-world case studies, we will explore different contexts of use, specifically focusing on the decision-making process for choosing between transwell, organoid and organ-chip models. This will include in-depth discussions on the critical role of cell sourcing and characterization in establishing trust and confidence in these models.
Date & Time
Tuesday, December 10, 2024, 10:30 AM ET - 12:00 PM ET
Duration
90 minutes
Agenda
Welcome and Introduction
Ratnakar Potla (Genentech)
Model-omics of Lung CIVMs
Ratnakar Potla (Genentech)
Introduction to context of use and validation expectations for Lung CIVM/MPS
Garrett Ainslie (AbbVie)
Case Study: Use of alveolar transwell and chip-based in vitro assay systems to model LRRK2 inhibitor-mediated increases in lamellar body size observed in nonclinical animals
Julie Harney (Pfizer)
Case Study: TBC
TBC
Q&A / Discussion
Ratnakar Potla (Genentech)
Garrett Ainslie (AbbVie)
Moderators and Presenters
Ratnakar Potla, PhD
Principal Scientist
Genentech-Roche
Ratnakar Potla is a physician scientist by training. He is currently a principal scientist in the Complex in vitro systems group within Genentech Research and early development (gRED) where he leads the lung team within Safety assessment. He supports the safety assessment of candidate molecules using complex in vitro systems like organ on chips and organoids using multiple commercially available and in house fabricated platforms.
Garrett R. Ainslie, PhD
Principal Research Scientist, Quantitative, Translational and ADME Sciences
AbbVie
Garrett Ainslie received his PhD in Toxicology from the University of North Carolina at Chapel Hill in 2014 and over 8 years of experience in the discovery and development of inhaled molecules. He currently leads inhalation discovery project teams and implements translational approaches at Abbvie.
Julie Harney, PhD
Senior Principal Scientist, Investigative Toxicology
Pfizer
Julie Harney is a Senior Principal Scientist in the Investigative Toxicology group within Drug Safety Research and Development at Pfizer. Her expertise in complex in vitro model development spans 15 years supporting nonclinical toxicological assessments across a wide variety of organ systems, therapeutic modalities and indications.
